This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia
Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia
The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications
Prognostic and Predictive Implications of Cytogenetics and Genomics
Genomics of Resistance to Targeted Therapies
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton`s Tyrosine Kinase Inhibitors
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond
구분 | 13시 이전 | 13시 이후 |
---|---|---|
군자도서 | 당일출고 | 1일 추가 |
타사도서 | 1일 ~ 2일 추가 | 2일 ~ 3일 추가 |
고객님께서 급히 필요하신 상품은 별도로 나누어 주문하시면 수령시간이 절약됩니다.
국내에서 재고를 보유한 업체가 없는 경우 해외주문을 해야 하는 상황이 생깁니다.
이 경우 4~5주 안에 공급이 가능하며 현지 출판사 사정에 따라 구입이 어려운 경우 2~3주 안에 공지해 드립니다.
# 재고 유무는 주문 전 사이트 상에서 배송 안내 문구로 구분 가능하며, 필요에 따라 전화 문의 주시면 거래처를 통해 다시 한번 국내재고를 확인해 드립니다.
전자상거래에 의한 소비자보호에 관한 법률에 의거 반품 가능 기간내에는 반품을 요청하실 수 있습니다.
(10881) 경기도 파주시 회동길 338 (서패동 474-1) 군자출판사빌딩 4층